Adalta Ltd has released a press release.
AD-214 Phase I strategy and timing update
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from AdAlta
- AdAlta awarded Biomedical Translation Bridge Funding
- GLP Toxicology study results
- Tim Oldham Appointed as Chief Executive Officer
- Receipt of R&D Tax Incentive
- AdAlta secures licensing deal with GE Healthcare
Later from AdAlta
- AdAlta Granted US Patent for AD-214
- Appendix 4C - quarterly
- AD-214 effective in gold standard pre-clinical animal model
- Investor Briefing - Strategic Plan
- Board changes and R&D Tax Incentive advance received
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta